Dyadic Applied BioSolutions and BRIG BIO announced the signing of a Development and Commercialization Agreement to jointly develop and commercialize recombinant bovine alpha-lactalbumin. Together, the companies aim to accelerate commercialization timelines, support commercially viable production, enhance market affordability, and expand global access to sustainable proteins with comparable functional properties to traditional dairy proteins. Under the terms of the agreement, BRIG BIO will fully fund the development program and receive a global commercial license to Dyadic’s production strains capable of producing alpha-lac developed in the Dapibus fungal expression system, and Dyadic will receive access and milestone payments and long-term shared revenue participation tied to commercial sales in addition to co-marketing and sales rights.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DYAI:
- Dyadic International’s Earnings Call: Cautious Optimism Amid Challenges
- Dyadic Applied BioSolutions Reports Q3 2025 Earnings and Strategic Shift
- Dyadic International reports Q3 EPS (6c), consensus (4c)
- Dyadic International, ERS Genomics announces CRISPR/Cas9 license
- Dyadic International Inc. (DYAI) Q3 Earnings Cheat Sheet